The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1L2FXT     bis[3-[(1R)-6,7-dimethoxy-2- methyl-1-[(3,4...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mivacurium


Psychiatry related information on Mivacurium


High impact information on Mivacurium


Chemical compound and disease context of Mivacurium


Biological context of Mivacurium


Anatomical context of Mivacurium


Associations of Mivacurium with other chemical compounds


Gene context of Mivacurium

  • In 38 patients who received mivacurium by continuous infusion (duration 88.1 +/- 7.1/47.1 min, SE/SD) for maintenance of 95 +/- 4% twitch inhibition, the mean 5-95% and 25-75% recovery indices after discontinuation of infusion were 14.4 +/- 0.6 and 6.5 +/- 0.3 min (P greater than 0.5 vs. all single bolus doses) [18].
  • CONCLUSIONS: After recovery from profound mivacurium-induced neuromuscular block, TOF counts of 1, 2, 3, and 4 approximate 10%, 20%, 30%, and 40% return to control twitch height, respectively [30].
  • The use of butyrylcholinesterase for antagonism of profound mivacurium-induced blockade has not been studied in humans [29].
  • RESULTS: Acetylcholinesterase was a poor hydrolyzer of mivacurium, as bioassayed by reversal of paralysis [31].
  • Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro [31].

Analytical, diagnostic and therapeutic context of Mivacurium


  1. Is intramuscular mivacurium an alternative to intramuscular succinylcholine? Cauldwell, C.B., Lau, M., Fisher, D.M. Anesthesiology (1994) [Pubmed]
  2. Sensitivity to mivacurium in a patient with mitochondrial myopathy. Naguib, M., el Dawlatly, A.A., Ashour, M., al-Bunyan, M. Anesthesiology (1996) [Pubmed]
  3. Duration of anesthesia before muscle relaxant injection influences level of paralysis. Plaud, B., Debaene, B., Donati, F. Anesthesiology (2002) [Pubmed]
  4. The cardiovascular effects of mivacurium in hypertensive patients. Plaud, B., Marty, J., Debaene, B., Meistelman, C., Pellissier, D., LePage, J.Y., Feiss, P., Scherpereel, P., Bouverne, M.N., Fosse, S. Anesth. Analg. (2002) [Pubmed]
  5. Use of mivacurium chloride by constant infusion in the anephric patient. Phillips, B.J., Hunter, J.M. British journal of anaesthesia. (1992) [Pubmed]
  6. Mivacurium in electroconvulsive therapy. Burnstein, R.M., Denny, N. Anaesthesia. (1993) [Pubmed]
  7. Sevoflurane and mivacurium in a patient with Huntington's chorea. Nagele, P., Hammerle, A.F. British journal of anaesthesia. (2000) [Pubmed]
  8. Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Atherton, D.P., Hunter, J.M. Clinical pharmacokinetics. (1999) [Pubmed]
  9. Response to mivacurium in patients carrying the k variant in the butyrylcholinesterase gene. Gätke, M.R., Viby-Mogensen, J., Ostergaard, D., Bundgaard, J.R. Anesthesiology (2005) [Pubmed]
  10. Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. Motamed, C., Menad, R., Farinotti, R., Kirov, K., Combes, X., Bouleau, D., Feiss, P., Duvaldestin, P. Anesthesiology (2003) [Pubmed]
  11. Phonomyography as a novel method to determine neuromuscular blockade at the laryngeal adductor muscles: comparison with the cuff pressure method. Hemmerling, T.M., Babin, D., Donati, F. Anesthesiology (2003) [Pubmed]
  12. The duration of immobilization causes the changing pharmacodynamics of mivacurium and rocuronium in rabbits. Kim, K.S., Jeon, J.W., Koh, M.S., Shim, J.H., Cho, S.Y., Suh, J.K. Anesth. Analg. (2003) [Pubmed]
  13. Is mivacurium chloride effective in electroconvulsive therapy? A report of four cases, including a patient with myasthenia gravis. Gitlin, M.C., Jahr, J.S., Margolis, M.A., McCain, J. Anesth. Analg. (1993) [Pubmed]
  14. Cisatracurium, but not mivacurium, inhibits survival and axonal growth of neonatal and adult rat peripheral neurons in vitro. Lirk, P., Longato, S., Rieder, J., Klimaschewski, L. Neurosci. Lett. (2004) [Pubmed]
  15. The effect on lung mechanics in anesthetized children with rapacuronium: a comparative study with mivacurium. Fine, G.F., Motoyama, E.K., Brandom, B.W., Fertal, K.M., Mutich, R., Davis, P.J. Anesth. Analg. (2002) [Pubmed]
  16. Doxacurium and mivacurium do not trigger malignant hyperthermia in susceptible swine. Sufit, R.L., Kreul, J.F., Bellay, Y.M., Helmer, P., Brunson, D.B., Will, J. Anesth. Analg. (1990) [Pubmed]
  17. Mivacurium arteriovenous gradient during steady state infusion in anesthetized patients. Ezzine, S., Donati, F., Varin, F. Anesthesiology (2002) [Pubmed]
  18. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug. Savarese, J.J., Ali, H.H., Basta, S.J., Embree, P.B., Scott, R.P., Sunder, N., Weakly, J.N., Wastila, W.B., el-Sayad, H.A. Anesthesiology (1988) [Pubmed]
  19. The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. Savarese, J.J., Ali, H.H., Basta, S.J., Scott, R.P., Embree, P.B., Wastila, W.B., Abou-Donia, M.M., Gelb, C. Anesthesiology (1989) [Pubmed]
  20. Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide. Goudsouzian, N.G., Denman, W., Schwartz, A., Shorten, G., Foster, V., Samara, B. Anesthesiology (1993) [Pubmed]
  21. Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene: genotyping by sequencing. Gätke, M.R., Ostergaard, D., Bundgaard, J.R., Varin, F., Viby-Mogensen, J. Anesthesiology (2001) [Pubmed]
  22. Differential sensitivity of abdominal muscles and the diaphragm to mivacurium: an electromyographic study. Kirov, K., Motamed, C., Dhonneur, G. Anesthesiology (2001) [Pubmed]
  23. Residual block after mivacurium with or without edrophonium reversal in adults and children. Bevan, D.R., Kahwaji, R., Ansermino, J.M., Reimer, E., Smith, M.F., O'Connor, G.A., Bevan, J.C. Anesthesiology (1996) [Pubmed]
  24. Mivacurium neuromuscular block at the adductor muscles of the larynx and adductor pollicis in humans. Plaud, B., Debaene, B., Lequeau, F., Meistelman, C., Donati, F. Anesthesiology (1996) [Pubmed]
  25. Role of endogenous histamine in altered lung mechanics in rabbits. Habre, W., Babik, B., Chalier, M., Peták, F. Anesthesiology (2002) [Pubmed]
  26. Clinical pharmacokinetics of neuromuscular blocking drugs. Agoston, S., Vandenbrom, R.H., Wierda, J.M. Clinical pharmacokinetics. (1992) [Pubmed]
  27. Onset of action of mivacurium chloride. A comparison of neuromuscular blockade monitoring at the adductor pollicis and the orbicularis oculi. Sayson, S.C., Mongan, P.D. Anesthesiology (1994) [Pubmed]
  28. The effect of neostigmine on twitch tension and muscle relaxant concentration during infusion of mivacurium or vecuronium. Szenohradszky, J., Lau, M., Brown, R., Sharma, M.L., Fisher, D.M. Anesthesiology (1995) [Pubmed]
  29. Enzymatic versus pharmacologic antagonism of profound mivacurium- induced neuromuscular blockade. Naguib, M., Selim, M., Bakhamees, H.S., Samarkandi, A.H., Turkistani, A. Anesthesiology (1996) [Pubmed]
  30. Antagonism of mivacurium-induced neuromuscular blockade in humans. Edrophonium dose requirements at threshold train-of-four count of 4. Kopman, A.F., Mallhi, M.U., Justo, M.D., Rodricks, P., Neuman, G.G. Anesthesiology (1994) [Pubmed]
  31. Pseudocholinesterase-mediated hydrolysis is superior to neostigmine for reversal of mivacurium-induced paralysis in vitro. Yang, H.S., Goudsouzian, N., Martyn, J.A. Anesthesiology (1996) [Pubmed]
  32. Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia. Frampton, J.E., McTavish, D. Drugs (1993) [Pubmed]
  33. The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. Ostergaard, D., Rasmussen, S.N., Viby-Mogensen, J., Pedersen, N.A., Boysen, R. Anesthesiology (2000) [Pubmed]
  34. Mivacurium when preceded by pancuronium becomes a long-acting muscle relaxant. Erkola, O., Rautoma, P., Meretoja, O.A. Anesthesiology (1996) [Pubmed]
WikiGenes - Universities